Aptorum Group Limited Class A Ordinary Shares (APM) Stock Price

APMStock

$4.82−72.46%52W

Market Cap$3.93M

P/E—

PEG Ratio—

Div yield—

Beta-1.79

APM Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-55.37%

Price vs S&P 500 (4W)-40.00%

VGM Score42.23

Book Value / Share (Quarterly)$2.84

P/TBV (Annual)0.37x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-0.23

Price vs S&P 500 (YTD)-67.94%

Gross Margin (TTM)7.10%

Net Profit Margin (TTM)-1115.14%

EPS (TTM)$-0.35

10-Day Avg Trading Volume0.06M

EPS Excl Extra (TTM)$-0.35

EPS (Annual)$-0.19

ROI (Annual)-5.11%

Gross Margin (Annual)2.45%

Net Profit Margin (5Y Avg)-1143.89%

Cash / Share (Quarterly)$0.42

ROA (Last FY)-7.29%

EBITD / Share (TTM)$-0.24

ROE (5Y Avg)-41.19%

Operating Margin (TTM)-1298.41%

Cash Flow / Share (Annual)$-0.23

P/B Ratio0.25x

P/B Ratio (Quarterly)0.37x

Net Income / Employee (Annual)$-1,363,300

EV / Revenue (TTM)4.78x

Net Interest Coverage (TTM)-4.53x

ROA (TTM)-12.07%

EPS Incl Extra (Annual)$-0.19

Current Ratio (Annual)0.78x

Quick Ratio (Quarterly)0.77x

3-Month Avg Trading Volume0.12M

52-Week Price Return-72.46%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$2.84

P/S Ratio (Annual)13.21x

Asset Turnover (Annual)0.02x

52-Week High$17.60

Operating Margin (5Y Avg)-2091.41%

EPS Excl Extra (Annual)$-0.19

Tangible BV CAGR (5Y)-10.74%

26-Week Price Return-38.44%

Quick Ratio (Annual)0.77x

13-Week Price Return-43.82%

Total Debt / Equity (Annual)0.15x

Current Ratio (Quarterly)0.78x

Enterprise Value$5.75M

Asset Turnover (TTM)0.07x

Book Value / Share Growth (5Y)9.92%

Revenue / Employee (Annual)$0

Inventory Turnover (Annual)28.05x

Pretax Margin (Annual)-1006.30%

Cash / Share (Annual)$0.42

3-Month Return Std Dev99.60%

Gross Margin (5Y Avg)-9.07%

Net Income / Employee (TTM)$-2,065,800

ROE (Last FY)-5.89%

Net Interest Coverage (Annual)-14.59x

EPS Basic Excl Extra (Annual)$-0.19

Receivables Turnover (TTM)0.00x

Total Debt / Equity (Quarterly)0.15x

EPS Incl Extra (TTM)$-0.35

Receivables Turnover (Annual)3.96x

ROI (TTM)-8.10%

P/S Ratio (TTM)4.75x

Pretax Margin (5Y Avg)-1367.78%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$2.84

Forward P/E0.23x

Price vs S&P 500 (52W)-88.43%

Year-to-Date Return-54.53%

5-Day Price Return1.05%

EPS Normalized (Annual)$-0.19

ROA (5Y Avg)-41.75%

Net Profit Margin (Annual)-654.79%

Month-to-Date Return-29.74%

Cash Flow / Share (TTM)$-2.89

EBITD / Share (Annual)$-0.25

Operating Margin (Annual)-2486.03%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-36.51%

LT Debt / Equity (Quarterly)0.14x

EPS Basic Excl Extra (TTM)$-0.35

P/TBV (Quarterly)0.37x

P/B Ratio (Annual)0.37x

Inventory Turnover (TTM)28.05x

Pretax Margin (TTM)-1282.26%

Book Value / Share (Annual)$2.84

Price vs S&P 500 (13W)-47.72%

Beta-1.79x

Revenue / Share (TTM)$0.00

ROE (TTM)-9.33%

52-Week Low$4.65

vGradeC

mGradeD

vgmGradeC

APM Analyst Recommendations

Jun 2023

Jul 2023

Aug 2023

Sep 2023

4.00

Industry Peers — Measuring & Controlling Devices(11)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth (5Y)	Gross Margin (TTM)	Operating Margin (TTM)	Price
APMAptorum Group Limited Class A Ordinary Shares	C	—	D	4.7x	—	7.1%	-1298.4%	$4.82
TMOThermo Fisher Scientific, Inc.	D	C	A	5.5x	6.7%	40.9%	17.6%	$690.00
ROKRockwell Automation, Inc.	D	C	B	5.3x	5.7%	54.5%	14.7%	$426.23
TRMBTrimble Inc. Common Stock	C	C	B	3.6x	-0.4%	70.5%	3.7%	$59.46
ONTOOnto Innovation Inc.	D	B	C	9.7x	12.6%	55.1%	12.0%	$220.70
MIRMirion Technologies, Inc.	C	B	C	3.7x	8.6%	48.0%	5.3%	$15.15
QSIQuantum-Si Incorporated Class A Common Stock	D	F	C	152.7x	—	35.0%	-6887.8%	$1.12
OWLTOwlet, Inc.	B	B	D	1.0x	7.0%	54.8%	-8.4%	$4.11
GEOSGeospace Technologies Corporation Common Stock	B	F	D	0.6x	4.8%	8.0%	-44.6%	$4.41
BCHTBirchtech Corp.	B	B	D	1.6x	16.6%	39.7%	-23.6%	$1.18
NIKINiki BioSolutions, Inc. Common Stock	—	—	F	5.3x	—	7.1%	-1298.4%	$2.03
CAPADefiance AI Capacitors & MLCC ETF	—	—	F	—	—	—	—	$23.84

About Aptorum Group Limited Class A Ordinary Shares

Aptorum Group develops clinical-stage therapeutics targeting oncology and infectious diseases, with emphasis on orphan cancer indications where treatment options are limited. Its pipeline includes ALS-4, SACT-1, and RPIDD programs, supported by healthcare services operations.